Effect of Tepotinib on PK of CYP3A Substrate Midazolam
Clinical trial NCT03628339 · COMPLETED
Trial details
- NCT number
- NCT03628339
- Sponsor
- Merck KGaA, Darmstadt, Germany
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2018-08-20
- Primary completion
- 2018-10-25
- Enrollment
- 12
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.